ChromaDex Corp. (CDXC), a commercial-stage global bioscience company, expects 2024 revenue to grow at a higher rate than the prior year growth of 16%.
The company derives most of its revenue from Tru Niagen, a supplement that is believed to slow or reverse the process of aging. Tru Niagen works by boosting Nicotinamide adenine dinucleotide plus (NAD+) and supports the body's natural cellular energy production.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com